Erectile Dysfunction News and Research RSS Feed - Erectile Dysfunction News and Research

Erectile Dysfunction (ED) is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women. [More]
Study on effects of cholesterol-lowering medications on sexual health

Study on effects of cholesterol-lowering medications on sexual health

A new study is giving hope to older men who are concerned about the effects of cholesterol-lowering medications on their sexual health. [More]
Popular cholesterol-lowering drugs may offer added benefit for men with erectile dysfunction

Popular cholesterol-lowering drugs may offer added benefit for men with erectile dysfunction

​Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Reversing erectile dysfunction possible with lifestyle changes

Reversing erectile dysfunction possible with lifestyle changes

Men suffering from sexual dysfunction can be successful at reversing their problem, by focusing on lifestyle factors and not just relying on medication, according to research at the University of Adelaide. [More]
Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014. [More]
NIH-funded session in Bethesda to heighten awareness of underactive bladder

NIH-funded session in Bethesda to heighten awareness of underactive bladder

Underactive bladder, estimated to affect more than 20 percent of the elderly population, is an unrecognized disease that has a major influence on the health and independence of seniors. [More]
Chesapeake Urology for Kids introduced for pediatric care

Chesapeake Urology for Kids introduced for pediatric care

Chesapeake Urology Associates, PA, the premier urology practice in Maryland and the Mid-Atlantic region, introduces Chesapeake Urology for Kids, a comprehensive program to treat urologic conditions in children from pre-natal to 18 years of age. This new division is being led by Robert Mevorach, MD, a fellowship trained pediatric urologist. An office exclusively for pediatric patients is now open at 25 Crossroads Drive in Owings Mills, Maryland. [More]
Surgeon general: Smoking linked to more than 30 diseases, conditions

Surgeon general: Smoking linked to more than 30 diseases, conditions

The report, which finds that smoking causes even more physical and financial damage than previously estimated, was released 50 years after the first report tied cigarettes to diseases. [More]

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii. [More]

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently. [More]
Potential dual benefits to tackling LUTS progression risk factors

Potential dual benefits to tackling LUTS progression risk factors

Research shows that several risk factors associated with Type 2 diabetes and cardiovascular disease also predict the progression of storage and voiding lower urinary tract symptoms in men, suggesting that targeting these could have multiple benefits. [More]

Study explains important link between ED and development of coronary artery disease

Erectile dysfunction is caused by the inability of the artery that supplies blood to the penis to expand and contract properly. The study of this mechanism has led to a new understanding of the important link between ED and the development of coronary artery disease, and to new strategies for prevention and treatment, as described in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. [More]

C4 Imaging receives FDA clearance for Sirius MRI Marker

C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure. [More]

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. [More]

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Women with moderate to severe menstrual cramps may find relief in a class of erectile dysfunction drugs, according to a team of researchers led by Penn State College of Medicines Richard Legro. [More]
Global health organizations join forces to raise awareness on dangers of fake medicines

Global health organizations join forces to raise awareness on dangers of fake medicines

Fake medicines increasingly put patients and the general public at risk across the world. In response to this challenge, ten partners who represent healthcare professionals, disease-specific organizations, product-development partnerships, foundations, international financing institutions, as well as the research-based pharmaceutical industry have joined forces to raise awareness about the dangers of fake medicines. [More]

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy. [More]
Sexual dysfunction ‘ignored in COPD’

Sexual dysfunction ‘ignored in COPD’

Researchers say that physicians should address sexual issues in patients with chronic obstructive pulmonary disease as a matter of course, after finding that over three-quarters of men with the condition have some level of erectile dysfunction. [More]

Auxilium Licenses Stendra From Vivus For Up To $300M

... [More]

Auxilium Licenses Stendra From Vivus For Up To $300M

... [More]